Medipure Holdings Inc. Announces a Filing of its Provisional Patent for Proprietary Prodrug Platform for Various Therapeutics
May 26th, 2021
Company Continues Building Momentum Stepping Toward Adding to its Pipeline of Game-changing Pharmaceutical Products
VANCOUVER, British Columbia, May 26, 2021 /PRNewswire-PRWeb/ — Medipure Pharmaceuticals Inc. (“MPI”), a wholly owned subsidiary of Medipure Holdings Inc. (together with MPI, “Medipure” or the “Company”), a biopharmaceutical incubator committed to discovering and developing proprietary prescription drugs focused on the endocannabinoid system, is pleased to announce the submission of provisional patent application to the United States Patent and Trademark Office (“USPTO”) for MP-40X technology entitled “PROPRIETARY PRODRUG MOLECULES PRODUCTION METHOD AND USES THEREOF” U.S. 63/171,952. This invention relates to endocannabinoid targeting prodrug production and its therapeutic use in a novel delivery system. The said technology has provided a robust formulation platform to Medipure’s drug candidates to strengthen its therapeutic profile.
“We are very pleased to secure the intellectual property regarding our core therapeutic technology platform by this submission,” stated Boris Weiss, Chairman and CEO of Medipure Holdings Inc. “Apart from the apparent business reasons, I am especially excited and appreciative of our world-class team and collaborators, who have spent years developing and finetuning MP-40X to get it where it is today and that much closer to market.”
Founded in 2014 and based in Vancouver, Canada with laboratories in Croatia and India and other locations in the pipeline globally, Medipure develops its core products targeting specific disease areas including pain management, anxiety and mood disorders, dermatology, nausea, appetite, oncology, arthritis, and fatty liver disease. The Company’s goal is to cultivate pharmaceutical products that are non-addictive, have no side effects or toxicity, better efficacy at lower doses, and are absorbed by the body much quicker, and are more efficient with a longer life span than current drugs available in the marketplace.
“MP-40X is a unique therapeutic platform that comprises a series of endocannabinoid targeting molecules and is a fantastic addition to our portfolio of intellectual property,” stated Dr. Nihar Pandey, Medipure’s Chief Scientific Officer. “These novel prodrugs are fast-acting and long-lasting molecules that complement Medipure’s drug discovery and development for our safe and effective endocannabinoid-targeted prescription medications.”
Medipure continues with its patent applications for MP-40X in additional markets through the Patent Cooperation Treaty and will provide updates accordingly.
Medipure is a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms.
Cautionary Note Regarding Forward Looking Information
This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward- looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur, negative of these terms, or other similar expressions intended to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: the expected medical benefits, viability, safety, efficacy, and dosing. Forward-looking statements are based on certain assumptions made by the Company in light of the experience and perception of historical trends, current conditions, and expected future developments and other factors it believes are appropriate, and are subject to risks and uncertainties. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties, and assumptions, readers should not place undue reliance on these forward-looking statements. Whether actual results, performance, or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions, and other factors, including the inherent uncertainty of product development; our patent application may not be successful, third-party claims relating to misappropriation of their intellectual property; and our reliance on current early-stage research regarding the medical benefits, viability, safety, efficacy, and dosing of MP-30X. If any of these risks or uncertainties materialize, or if assumptions underlying the forward-looking statements prove incorrect, actual results might vary materially from those anticipated in the forward-looking statements.
Information contained in forward-looking statements in this news release is provided as of the date of this news release, and we disclaim any obligation to update any forward-looking statements, whether as a result of new information or future events or results, except to the extent required by applicable securities laws. Accordingly, readers should not place undue reliance on forward-looking statements or the information contained in those statements.
Doug Coupe, BOLD Communications Group, 843.568.2455, email@example.com
SOURCE Medipure Holdings Inc.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.